GE Medical Systems has signed licensing agreements with the Texas A&M University system and Beth Israel Deaconess Medical Center to develop new near-infrared-light imaging technologies. Efforts will focus on assessing the potential of these technologies
GE Medical Systems has signed licensing agreements with the Texas A&M University system and Beth Israel Deaconess Medical Center to develop new near-infrared-light imaging technologies. Efforts will focus on assessing the potential of these technologies to improve the detection, diagnosis, and treatment of cancers. The licensing agreements call for GE to work with the research institutions to advance technologies there for eventual FDA approval.
The A&M system technology, fluorescence-enhanced optical imaging and tomography, combines imaging sensitivity, tissue penetration, and tissue characterization as the means to detect and track disease progression. It also might be used in the development of new diagnostic and therapeutic agents. The Beth Israel Deaconess technology is an intraoperative near-infrared fluorescence imaging system that enables surgeons to visualize surgical anatomy and functional fluorescence simultaneously, noninvasively, and with high spatial resolution. Potential applications include image-guided sentinel lymph node mapping, image-guided cancer resection with real-time assessment of surgical margins, mapping of tumor and normal vasculature, image-guided avoidance of critical structures such as nerves, and detection of occult metastases.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.